Seegene, Inc. (096530.KQ)
KRW 23550.0
(-1.26%)
KRW 23550.0
(-1.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 210.08 Billion KRW | -26.35% |
| 2022 | 285.22 Billion KRW | -27.25% |
| 2021 | 392.07 Billion KRW | 135.44% |
| 2020 | 166.52 Billion KRW | 238.08% |
| 2019 | 49.25 Billion KRW | -1.51% |
| 2018 | 50.01 Billion KRW | 3.7% |
| 2017 | 48.22 Billion KRW | 33.2% |
| 2016 | 36.2 Billion KRW | 11.75% |
| 2015 | 32.4 Billion KRW | -7.6% |
| 2014 | 35.06 Billion KRW | 12.29% |
| 2013 | 31.22 Billion KRW | 28.26% |
| 2012 | 24.34 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 54.12 Billion KRW | 4.86% |
| 2024 Q2 | 53.41 Billion KRW | -1.3% |
| 2023 Q2 | 49.11 Billion KRW | -8.99% |
| 2023 Q1 | 53.96 Billion KRW | -3.57% |
| 2023 FY | 210.08 Billion KRW | -26.35% |
| 2023 Q4 | 51.61 Billion KRW | -6.81% |
| 2023 Q3 | 55.38 Billion KRW | 12.77% |
| 2022 Q3 | 69.35 Billion KRW | 0.94% |
| 2022 Q2 | 68.7 Billion KRW | -24.75% |
| 2022 Q4 | 55.96 Billion KRW | -19.3% |
| 2022 Q1 | 91.3 Billion KRW | -25.52% |
| 2022 FY | 285.22 Billion KRW | -27.25% |
| 2021 Q1 | 69.44 Billion KRW | -24.95% |
| 2021 Q3 | 75.19 Billion KRW | 5.3% |
| 2021 FY | 392.07 Billion KRW | 135.44% |
| 2021 Q4 | 122.59 Billion KRW | 63.03% |
| 2021 Q2 | 71.4 Billion KRW | 2.84% |
| 2020 Q1 | 18.34 Billion KRW | 21.37% |
| 2020 Q3 | 46.32 Billion KRW | 50.45% |
| 2020 Q4 | 92.53 Billion KRW | 99.74% |
| 2020 FY | 166.52 Billion KRW | 238.08% |
| 2020 Q2 | 30.79 Billion KRW | 67.81% |
| 2019 FY | 49.25 Billion KRW | -1.51% |
| 2019 Q3 | 13.9 Billion KRW | 18.22% |
| 2019 Q4 | 15.11 Billion KRW | 8.75% |
| 2019 Q2 | 11.75 Billion KRW | -10.49% |
| 2019 Q1 | 13.13 Billion KRW | -11.63% |
| 2018 Q1 | 14.35 Billion KRW | -17.85% |
| 2018 FY | 50.01 Billion KRW | 3.7% |
| 2018 Q4 | 14.86 Billion KRW | 12.07% |
| 2018 Q3 | 13.26 Billion KRW | -8.81% |
| 2018 Q2 | 14.54 Billion KRW | 1.34% |
| 2017 Q3 | 12.47 Billion KRW | 0.87% |
| 2017 Q2 | 12.36 Billion KRW | -12.39% |
| 2017 Q1 | 14.11 Billion KRW | 77.07% |
| 2017 Q4 | 17.47 Billion KRW | 40.06% |
| 2017 FY | 48.22 Billion KRW | 33.2% |
| 2016 FY | 36.2 Billion KRW | 11.75% |
| 2016 Q1 | 10.37 Billion KRW | -11.6% |
| 2016 Q2 | 10.42 Billion KRW | 0.55% |
| 2016 Q3 | 13.19 Billion KRW | 26.55% |
| 2016 Q4 | 7.97 Billion KRW | -39.58% |
| 2015 Q2 | 8.23 Billion KRW | -16.87% |
| 2015 Q1 | 9.9 Billion KRW | 24.7% |
| 2015 Q4 | 11.73 Billion KRW | 64.82% |
| 2015 FY | 32.4 Billion KRW | -7.6% |
| 2015 Q3 | 7.11 Billion KRW | -13.57% |
| 2014 Q1 | 8.81 Billion KRW | -12.28% |
| 2014 FY | 35.06 Billion KRW | 12.29% |
| 2014 Q4 | 7.94 Billion KRW | -1.53% |
| 2014 Q3 | 8.06 Billion KRW | -21.21% |
| 2014 Q2 | 10.24 Billion KRW | 16.23% |
| 2013 Q4 | 10.04 Billion KRW | 18.95% |
| 2013 Q2 | 6.84 Billion KRW | 16.17% |
| 2013 FY | 31.22 Billion KRW | 28.26% |
| 2013 Q3 | 8.44 Billion KRW | 23.33% |
| 2013 Q1 | 5.89 Billion KRW | -20.5% |
| 2012 Q4 | 7.41 Billion KRW | 19.32% |
| 2012 Q3 | 6.21 Billion KRW | 0.0% |
| 2012 FY | 24.34 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 78.35 Billion KRW | -168.104% |
| InBody Co.,Ltd | 87.36 Billion KRW | -140.464% |
| Curexo Inc. | 18.16 Billion KRW | -1056.643% |
| i-SENS, Inc. | 91.12 Billion KRW | -130.532% |
| Ray Co., Ltd. | 59.03 Billion KRW | -255.876% |
| Gencurix Inc. | 12.79 Billion KRW | -1541.508% |
| Sugentech Inc. | 18.6 Billion KRW | -1029.259% |
| L&C Bio Co., Ltd | 25.86 Billion KRW | -712.359% |